PE20230159A1 - Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos - Google Patents

Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos

Info

Publication number
PE20230159A1
PE20230159A1 PE2022001098A PE2022001098A PE20230159A1 PE 20230159 A1 PE20230159 A1 PE 20230159A1 PE 2022001098 A PE2022001098 A PE 2022001098A PE 2022001098 A PE2022001098 A PE 2022001098A PE 20230159 A1 PE20230159 A1 PE 20230159A1
Authority
PE
Peru
Prior art keywords
alkyl
oxoisoindolin
piperidin
methoxy
dione
Prior art date
Application number
PE2022001098A
Other languages
English (en)
Inventor
Simone Bonazzi
Artiom Cernijenko
Jennifer Stroka Cobb
Natalie Dales
John Ryan Kerrigan
Philip Lam
Hasnain Ahmed Malik
Gary O'brien
Andrew W Patterson
Noel Marie-France Thomsen
Pamela Ting
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20230159A1 publication Critical patent/PE20230159A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a compuestos derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona de formula (I'); en donde Y es O, CH2, CF2, y CHF; z es de 0 a 2; RX1 y RX2 es cada uno, independientemente, H y alquilo C1-C6; RY1 y RY2 es cada uno, independientemente, H y alquilo C1-C6; RZ1 y RZ2 son ambos hidrogeno; R1 es H y alquilo C1-C6; R2 es H, -C(=O)-R3 , cicloalquilo C3-C8, haloalquilo C1-C6 y alquilo C1-C10. Un compuesto seleccionado es 3-(5-(((R)-1-((1-ciclohexil-1H-pirazol-4-il)metil) piperidin-2-il)metoxi)-1-oxoisoindolin-2- il)piperidin-2,6-diona. Tambien refiere a una composicion farmaceutica que los comprende. Dichos compuestos son efectivos para reducir los niveles de expresion de la proteina Motivos de Dedos de Zinc Ampliamente Interespaciados (WIZ) y/o para inducir la expresion de la hemoglobina fetal (HbF), siendo util en el tratamiento de trastornos sanguineos hereditarios (hemoglobinopatias, beta-hemoglobinopatias), tales como la enfermedad de celulas falciformes y la betatalasemia.
PE2022001098A 2019-12-18 2020-12-16 Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos PE20230159A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962950048P 2019-12-18 2019-12-18
PCT/IB2020/062070 WO2021124172A1 (en) 2019-12-18 2020-12-16 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof

Publications (1)

Publication Number Publication Date
PE20230159A1 true PE20230159A1 (es) 2023-02-01

Family

ID=73856242

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001098A PE20230159A1 (es) 2019-12-18 2020-12-16 Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos

Country Status (20)

Country Link
US (1) US11566022B2 (es)
EP (1) EP4076650B1 (es)
JP (1) JP2023506642A (es)
KR (1) KR20220114065A (es)
CN (1) CN114828959B (es)
AR (1) AR120773A1 (es)
AU (1) AU2020410514A1 (es)
BR (1) BR112022011796A2 (es)
CA (1) CA3164832A1 (es)
CO (1) CO2022008243A2 (es)
CR (1) CR20220278A (es)
DO (1) DOP2022000121A (es)
EC (1) ECSP22055267A (es)
IL (1) IL293530A (es)
JO (1) JOP20220152A1 (es)
MX (1) MX2022007351A (es)
PE (1) PE20230159A1 (es)
TW (1) TW202130631A (es)
UY (1) UY38986A (es)
WO (1) WO2021124172A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.
PE20240657A1 (es) * 2021-06-03 2024-04-04 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos medicos
WO2023006097A1 (zh) * 2021-07-30 2023-02-02 海创药业股份有限公司 一种双功能嵌合体杂环化合物及其作为雄激素受体降解剂的用途
CN115959976A (zh) * 2022-12-30 2023-04-14 安徽诺全药业有限公司 一种甲氧基取代双环戊烷衍生物的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013269A1 (es) 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20020160393A1 (en) 2000-12-28 2002-10-31 Symonds Geoffrey P. Double-stranded RNA-mediated gene suppression
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
NZ717149A (en) * 2010-02-11 2017-06-30 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same for treating various diseases
AU2011329619A1 (en) 2010-11-18 2013-05-02 Deuteria Pharmaceuticals, Inc. 3-deutero-pomalidomide
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EP2877462B1 (en) 2012-07-27 2019-09-04 Celgene Corporation Processes for preparing isoindoline-1,3-dione compounds
EP3331613A4 (en) 2015-08-04 2019-04-17 Celgene Corporation METHOD FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA AND USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES
CA3018434A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
US10584101B2 (en) 2016-10-11 2020-03-10 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
CA3209295A1 (en) 2016-11-01 2018-06-07 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
HRP20231537T1 (hr) 2016-12-01 2024-03-15 Arvinas Operations, Inc. Derivati tetrahidronaftalena i tetrahidroizokinolina kao degradatori estrogenskih receptora
CA3047586A1 (en) 2016-12-23 2018-06-28 Arvinas Operations, Inc. Egfr proteolysis targeting chimeric molecules and associated methods of use
US10723717B2 (en) 2016-12-23 2020-07-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
US10604506B2 (en) 2017-01-26 2020-03-31 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
KR20200086278A (ko) * 2017-10-18 2020-07-16 노파르티스 아게 선택적 단백질 분해를 위한 조성물 및 방법
US11505560B2 (en) 2017-10-20 2022-11-22 Dana-Farber Cancer Institute, Inc. Heterobifunctional compounds with improved specificity
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
JP2021508703A (ja) 2017-12-26 2021-03-11 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
EP3765026A4 (en) 2018-03-10 2021-12-22 Yale University BTK PROTEOLYSIS MODULATORS AND METHODS FOR USE
JP2021519337A (ja) * 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓの分解のためのセレブロン結合剤
JP2021521112A (ja) 2018-04-04 2021-08-26 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． タンパク質分解の調節因子および関連する使用方法
CA3102217A1 (en) 2018-06-29 2020-01-02 Dana-Farber Cancer Institute, Inc. Bispecific degraders
CA3102214A1 (en) 2018-06-29 2020-01-02 Dana-Farber Cancer Institute, Inc. Ligands to cereblon (crbn)
KR20210027395A (ko) 2018-06-29 2021-03-10 다나-파버 캔서 인스티튜트 인크. 면역조절 화합물
EP3813834A4 (en) 2018-06-29 2022-03-09 Dana Farber Cancer Institute, Inc. NEW CRBN MODULATORS
US20220177443A1 (en) 2018-12-03 2022-06-09 Dana-Farber Cancer Institute, Inc. Small molecule degraders of helios and methods of use

Also Published As

Publication number Publication date
CO2022008243A2 (es) 2022-07-08
US11566022B2 (en) 2023-01-31
AR120773A1 (es) 2022-03-16
IL293530A (en) 2022-08-01
CN114828959B (zh) 2024-04-02
CA3164832A1 (en) 2021-06-24
EP4076650B1 (en) 2024-02-28
EP4076650A1 (en) 2022-10-26
JOP20220152A1 (ar) 2023-01-30
AU2020410514A1 (en) 2022-06-30
US20220402904A1 (en) 2022-12-22
MX2022007351A (es) 2022-07-19
JP2023506642A (ja) 2023-02-17
UY38986A (es) 2021-07-30
ECSP22055267A (es) 2022-08-31
KR20220114065A (ko) 2022-08-17
DOP2022000121A (es) 2022-08-15
WO2021124172A1 (en) 2021-06-24
TW202130631A (zh) 2021-08-16
CN114828959A (zh) 2022-07-29
BR112022011796A2 (pt) 2022-08-30
CR20220278A (es) 2022-07-01

Similar Documents

Publication Publication Date Title
PE20230159A1 (es) Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
HRP20180199T1 (hr) Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom i (fprl-1)
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
RU2014129742A (ru) Производные бензолсульфонамида в качестве модуляторов rorc
AR104714A1 (es) Compuestos depsipeptídicos como antihelmínticos
JP2018504393A5 (es)
BR112022010599A2 (pt) Formas sólidas de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico, sal de 1,3-dihidróxi-2-(hidroximetil)propan-2-amina
EA023500B1 (ru) Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
AR100463A1 (es) Composiciones pesticidas y métodos relacionados
CY1116168T1 (el) Συγκρυσταλλοι και αλατα αναστολεων toy ccr3
BR112014015402A2 (pt) composição sólida de cuidado pessoal, produto de cuidado pessoal e método de tratar cabelo e/ou pele
RU2012158142A (ru) Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
AR065628A1 (es) Compuestos triciclicos de utilidad en el tratamiento de trastornos por carencia de hierro en el organismo
BR112014024479A8 (pt) Formulações farmacêuticas compreendendo antagonistas de c-cr3
PE20151666A1 (es) Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
AR126052A1 (es) Derivados de 3-(5-oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos
PE20220219A1 (es) Analogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluor-metil)pirimidin-5-il]etil}benzamida
JP2010520242A5 (es)
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
AR082137A1 (es) Derivados de bisaril(tio)morfolina como modulares s1p y composiciones farmaceuticas que los contienen
IE67814B1 (en) Use of heterocyclic amino-alcohol compounds for treatment of CNS diseases
RU2018130994A (ru) Новое соединение бисфосфоновой кислоты